Pankreas Kanseri
Özet
Pankreas kanseri hızlı gidişli, mortalitesi yüksek bir hastalıktır. Hastalar tanı anında genelde ileri evrede olup küratif tedavi seçeneğine uygun bulunmamaktadır. Küratif cerrahiye uygun olan hastaların adjuvan tedaviye rağmen nüks riski özellikle ilk 2 yıl oldukça yüksektir. Bu nedenle takip programları önem kazanmıştır. Hem lokal nüksü hem de metastazları erkenden saptamak için kılavuzlar arasında görüş birliği olmasa da nüks riskinin yüksek olduğu ilk iki yıl 3-6 ayda bir fizik muayene, serum CA 19-9 düzeyi ve kesitsel görüntülemeler ile takibi uygundur. Daha sonra 5 yıla kadar 6 ayda bir izlem, 5 yıldan sonra ise özellikle yıllık izlem önerilmektedir. Bu takip önerileri ülkelere, merkezlere göre değişebilmektedir.
Pancreatic cancer is a rapidly progressing disease with a high mortality rate. At the time of diagnosis, most patients are in advanced stages and are not suitable candidates for curative treatment options. Even for patients eligible for curative surgery, the risk of recurrence remains particularly high during the first two years despite adjuvant therapy. Therefore, follow-up programs play a crucial role. While there is no consensus among guidelines, it is appropriate to monitor patients during the first two years of high recurrence risk every 3-6 months with physical examinations, serum CA 19-9 levels, and cross-sectional imaging. Subsequently, follow-up every 6 months up to five years and annual monitoring after five years are generally recommended. These follow-up recommendations may vary between countries and medical centers.
Referanslar
Lai ECH, Ung AKY. Update on management of pancreatic cancer: a literature review. Chinese Clinical Oncology; Vol 13, No 3 (June 30, 2024): Chinese Clinical Oncology. 2024.
The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934-47.
Lowenfels AB, Maisonneuve P, Whitcomb DC. Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am. 2000;84(3):565-73.
Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. Jama. 2001;286(8):921-9.
Capasso M, Franceschi M, Rodriguez-Castro KI, Crafa P, Cambiè G, Miraglia C, et al. Epidemiology and risk factors of pancreatic cancer. Acta Biomed. 2018;89(9-s):141-6.
Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Annals of Oncology. 2023;34(11):987-1002.
Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11-26.
Kirkegård J, Gaber C, Heide-Jørgensen U, Fristrup CW, Lund JL, Cronin-Fenton D, et al. Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation. J Natl Cancer Inst. 2024;116(7):1072-9.
Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018;267(5):936-45.
Schawkat K, Manning MA, Glickman JN, Mortele KJ. Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils. Radiographics. 2020;40(5):1219-39.
Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7(5):189-97.
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v56-68.
Morris-Stiff G, Taylor MA. Ca19-9 and pancreatic cancer: Is it really that good? J Gastrointest Oncol. 2012;3(2):88-9.
Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006;141(10):968-73; discussion 74.
Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93(7):740-3.
Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005;9(9):1286-92.
Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11.
Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. Jama. 2021;326(9):851-62.
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-27.
Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39(22):2497-505.
Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106(12):1590-601.
Larsson P, Søreide K. Surgery for oligometastatic pancreatic cancer: next frontier? Br J Surg. 2024;111(1).
Omiya K, Maekawa A, Oba A, Inoue Y, Hirose Y, Kobayashi K, et al. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Br J Surg. 2024;111(1).
Sheffield KM, Crowell KT, Lin YL, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19(5):1670-7.
Andersson R, Ansari D, Haglund C. Surveillance after resection of pancreatic ductal adenocarcinoma: How to do it and what are the benefits? Scand J Surg. 2024;113(2):184-5.
Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541-56.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439-57.
Halle-Smith JM, Hall L, Daamen LA, Hodson J, Pande R, Young A, et al. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology. 2021;47(9):2248-55.
Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, et al. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013;20(7):2197-203.
Daamen LA, Groot VP, Heerkens HD, Intven MPW, van Santvoort HC, Molenaar IQ. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. HPB (Oxford). 2018;20(4):297-304.
Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501-3.
Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, et al. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018;25(12):3483-91.
Li J, Li Z, Kan H, Sun Z, Xing J, Cheng Y, et al. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. Pancreatology. 2019;19(2):302-6.
Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MPW, et al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Eur J Radiol. 2018;106:128-36.
Ruf J, Lopez Hänninen E, Oettle H, Plotkin M, Pelzer U, Stroszczynski C, et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology. 2005;5(2-3):266-72.
Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, et al. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clin Cancer Res. 2017;23(20):6094-100.
